EUVIMEDOpdag EUVIMED
Crossref

Treatment of hemiplegic migraine with anti‐calcitonin gene‐related peptide monoclonal antibodies: A case series in a tertiary‐care headache center

Daisuke Danno iD, Kumiko Ishizaki, Shoji Kikui, Takao Takeshima

Headache: The Journal of Head and Face Pain · 2023

DOI: 10.1111/head.14591 ↗

At a glance

Journal article in Headache: The Journal of Head and Face Pain, 2023. Written by Daisuke Danno and 3 co-authors. Institution: Headache Center, Department of Neurology, Tominaga Hospital, Osaka, Japan. Major MEDLINE topics: Migraine with Aura, Migraine Disorders, Epilepsy. Cited 15 times so far (Crossref); 20 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Hemiplegic migraine (HM) is a subtype of migraine with aura that includes motor weakness; such headaches can be excruciating. The presence of not only headache but also aura symptoms of HM increase the burden on patients, and the treatment of HM is sometimes challenging. Monoclonal antibodies (mAbs) targeting the calcitonin gene‐related peptide (CGRP) pathway are novel migraine preventive treatments that have shown promising efficacy in patients with migraine; however, there have been no reports regarding their efficacy in HM to date. Six patients with HM were treated with galcanezumab in a tertiary‐care headache center. After 3 months of treatment, the number of monthly days with headache of at least moderate severity was reduced in three patients. The number of days each month with weakness was also reduced in four patients. Furthermore, the Patient's Global Impression of Change and change in Migraine Disability Assessment total score, were improved in five of the six patients after the treatment; however, the change from baseline in days with bothersome symptoms did not show any specific trends in our patients. Notably, no adverse events were reported during the treatments. The mechanism underlying the improvement in aura symptoms in our patients is not clear; however, we speculate that a small amount of CGRP mAbs have a direct mode of action in the central nervous system; alternatively, blocking the CGRP pathway in the periphery may secondarily inhibit cortical spreading depression. While prudence must be practiced, galcanezumab was still generally effective in HM and well tolerated. Further prospective clinical studies will more clearly elucidate the effects of CGRP mAbs in patients with HM.

Subjects

MeSH terms (MEDLINE)

Migraine with AuraMigraine DisordersEpilepsyHumansCalcitonin Gene-Related PeptideTreatment OutcomeHemiplegiaAntibodies, MonoclonalHeadache

Author keywords

calcitonin gene-related peptidecortical spreading depressiongalcanezumabmigraine with aura

Substances

Calcitonin Gene-Related PeptideAntibodies, Monoclonal

Authors and institutions

  • Headache Center, Department of Neurology, Tominaga Hospital, Osaka, Japan.

ORCID profiles: Daisuke Danno

Cite

APA

Danno, D., Ishizaki, K., Kikui, S., & Takeshima, T. (2023). Treatment of hemiplegic migraine with anti‐calcitonin gene‐related peptide monoclonal antibodies: A case series in a tertiary‐care headache center. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14591

Vancouver

Danno D, Ishizaki K, Kikui S, Takeshima T. Treatment of hemiplegic migraine with anti‐calcitonin gene‐related peptide monoclonal antibodies: A case series in a tertiary‐care headache center. Headache: The Journal of Head and Face Pain. 2023. doi:10.1111/head.14591

BibTeX
@article{Danno2023,
  author = {Danno, Daisuke and Ishizaki, Kumiko and Kikui, Shoji and Takeshima, Takao},
  title = {Treatment of hemiplegic migraine with anti‐calcitonin gene‐related peptide monoclonal antibodies: A case series in a tertiary‐care headache center},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2023},
  doi = {10.1111/head.14591}
}
Start for free →